Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

The Food and Drug Administration approved oral Nubeqa plus the chemotherapy docetaxel for patients with metastatic hormone-sensitive prostate cancer. The Food and Drug Administration (FDA) approved ...

Prostate cancer is one of the most common cancers in the U.S., with an estimated 288,300 new cases and nearly 35,000 deaths expected in 2023. 2 Approximately 10 to 15 percent of patients with mCRPC ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Your prostate is an organ that makes some of the fluid that’s part of semen. It’s below your bladder and in front of your rectum. Prostate cancer happens when the cells in your prostate gland grow out ...

Benign prostatic hyperplasia (BPH) and prostate cancer are two of the most common conditions that affect the prostate, a gland that’s part of the male reproductive system. Positioned below the bladder ...

While most prostate cancers grow slowly, some may classify as aggressive prostate cancers based on stage and grade. Prostate cancers mostly consist of adenocarcinomas, which develop within the ...

In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval date: Note: The FDA’s information is current as of Dec. 18. 1. Phytonadione ...

High risk prostate cancer means that tumors may be at risk of spreading beyond the prostate or have already done so. Prostate cancers are divided into one of three risk groups: low, intermediate, and ...

Prostate cancer often has no symptoms early on, but you may later have frequent urination and a weak urine stream. Blood in your urine or semen can be a sign of prostate cancer as the disease ...